Clinical Decision Analysis of Genetic Evaluation and Testing in 1013 Intensive Care Unit Infants with Congenital Heart Defects Supports Universal Genetic Testing
Genes · 2024
DOI: 10.3390/genes15040505 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, 2024. Verfasst von Benjamin M Helm und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical & Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 46202, USA. Hauptthemen laut MEDLINE: Heart Defects, Congenital, Genetic Testing. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, American Heart Association-American Stroke Association, NIH HHS.
Themen: Intensivpflege
Abstract (Originalsprache)
Extracardiac anomalies (ECAs) are strong predictors of genetic disorders in infants with congenital heart disease (CHD), but there are no prior studies assessing performance of ECA status as a screen for genetic diagnoses in CHD patients. This retrospective cohort study assessed this in our comprehensive inpatient CHD genetics service focusing on neonates and infants admitted to the intensive care unit (ICU). The performance and diagnostic utility of using ECA status to screen for genetic disorders was assessed using decision curve analysis, a statistical tool to assess clinical utility, determining the threshold of phenotypic screening by ECA versus a Test-All approach. Over 24% of infants had genetic diagnoses identified (n = 244/1013), and ECA-positive status indicated a 4-fold increased risk of having a genetic disorder. However, ECA status had low–moderate screening performance based on predictive summary index, a compositive measure of positive and negative predictive values. For those with genetic diagnoses, nearly one-third (32%, 78/244) were ECA-negative but had cytogenetic and/or monogenic disorders identified by genetic testing. Thus, if the presence of multiple congenital anomalies is the phenotypic driver to initiate genetic testing, 13.4% (78/580) of infants with isolated CHD with identifiable genetic causes will be missed. Given the prevalence of genetic disorders and limited screening performance of ECA status, this analysis supports genetic testing in all CHD infants in intensive care settings rather than screening based on ECA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical & Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
- Department of Epidemiology, Indiana University Fairbanks School of Public Health, Indianapolis, IN 46202, USA.
- Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
ORCID-Profile: Benjamin M Helm
Förderung
- NHLBI NIH HHS
- American Heart Association-American Stroke Association
- NIH HHS
- Indiana University School of Medicine Strategic Research Initiative (SRI)
- Physician Scientist Initiative (PSI)
- American Heart Association Transformational Project Award AHA 19TPA34850054
- National Institute of Health P01 HL 1345599 (SMW)
Zitieren
APA
Helm, B. M., & Ware, S. M. (2024). Clinical Decision Analysis of Genetic Evaluation and Testing in 1013 Intensive Care Unit Infants with Congenital Heart Defects Supports Universal Genetic Testing. Genes. https://doi.org/10.3390/genes15040505
Vancouver
Helm BM, Ware SM. Clinical Decision Analysis of Genetic Evaluation and Testing in 1013 Intensive Care Unit Infants with Congenital Heart Defects Supports Universal Genetic Testing. Genes. 2024. doi:10.3390/genes15040505
BibTeX
@article{Helm2024,
author = {Helm, Benjamin M and Ware, Stephanie M},
title = {Clinical Decision Analysis of Genetic Evaluation and Testing in 1013 Intensive Care Unit Infants with Congenital Heart Defects Supports Universal Genetic Testing},
journal = {Genes},
year = {2024},
doi = {10.3390/genes15040505}
}
EUVIMED